| Disease Specific Interactions between Host Protein and DME (HOSPPI) |
| Drug co-metabolism |
| Cometabolized drug: ANW-32821 |
Click to Show/Hide the Full List of HOSPPI: 4 HOSPPI
|
| Cholesterol 24-hydroxylase (CYP46A1) |
Click to Show/Hide the Cometabolization Info |
| DME ID |
DME0028
DME Info
|
| Uniprot ID |
|
| Interaction Name |
CYP46A1-cyp142 interaction |
[1], [2] |
| Description |
The interaction, between human Cholesterol 24-hydroxylase and Cytochrome P450 142A2 from Mycolicibacterium smegmatis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism. |
| Cholesterol desmolase (CYP11A1) |
Click to Show/Hide the Cometabolization Info |
| DME ID |
DME0099
DME Info
|
| Uniprot ID |
|
| Interaction Name |
CYP11A1-cyp142 interaction |
[1], [2] |
| Description |
The interaction, between human Cholesterol desmolase and Cytochrome P450 142A2 from Mycolicibacterium smegmatis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism. |
| Cytochrome P450 7A1 (CYP7A1) |
Click to Show/Hide the Cometabolization Info |
| DME ID |
DME0624
DME Info
|
| Uniprot ID |
|
| Interaction Name |
CYP7A1-cyp142 interaction |
[1], [2] |
| Description |
The interaction, between human Cytochrome P450 7A1 and Cytochrome P450 142A2 from Mycolicibacterium smegmatis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism. |
| Vitamin D(3) 25-hydroxylase (CYP27A1) |
Click to Show/Hide the Cometabolization Info |
| DME ID |
DME0026
DME Info
|
| Uniprot ID |
|
| Interaction Name |
CYP27A1-cyp142 interaction |
[1], [2] |
| Description |
The interaction, between human Vitamin D(3 25-hydroxylase and Cytochrome P450 142A2 from Mycolicibacterium smegmatis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism. |
|
|
|
|
|
|